Skip to main content

Table 2 Demographic and clinical characteristics of HCV infected patients with different therapeutic response

From: SOCS3 mRNA expression and polymorphisms as pretreatment predictor of response to HCV genotype 3a IFN-based treatment

 

Overall mean/median

SVR mean/median

Non-responders/relapser mean/median

p value

Gender (n,  %)

 Male

85 (60.2 %)

66 (77.6 %)

19 (22.3 %)

0.317

 Female

56 (39.7 %)

49 (87.5 %)

7 (12.5 %)

 

Body mass index (kg/m2)

22.43 ± 4.3

22.31 ± 3.5

22.98 ± 7.2

0.48

Age (years)

40.0 ± 9.5

39.2 ± 8.9

43.58 ± 11.6

0.0344

ALT (IU/ml)

90.9 ± 65.5

64.5 ± 41

203.27 ± 7.2

0.0001

AST (IU/ml)

102.34 ± 84.1

73.64 ± 48.3

229.31 ± 92.1

0.0001

Albumin (g/l)

40.95 ± 10.56

41.23 ± 10.98

39.76 ± 8.54

0.52

Total Bilirubin (mg/dl)

23.93 ± 8.22

23.2 ± 7.32

27.2 ± 10.98

0.024

Fasting serum glucose (mg/l)a

95 (82–99)

94 (83–99)

96 (82–99)

0.84

Fasting insulin (μU/ml)a

6.5 (3–9)

6 (3–9)

7 (4–4.7)

0.43

HOMA-IRa

1.29 (0.74–3.25)

1.12 (0.74–2.11)

1.46 (0.77–3.25)

0.45

Viral titer (IU/ml)

 <100,000

68

56

12

0.706

 >100,000

73

59

14

 
  1. p ≤ 0.05 statistically significant
  2. aData only available for 87 patients